Analysts set out what Novo Nordisk has to show at its Capital Markets Day

Novo Nordisk will lay out its strategy, operations and financial targets at a Capital Markets Day in London on September 21, the first such event under CEO Mike Doustdar.^[1] Analyst previews from MedWatch and TIKR converge on a similar checklist: credible long-term sales and margin targets, a pipeline that survives the recent collapse of the heart-drug candidate ziltivekimab, manufacturing plans that avoid repeating past Wegovy supply shortages, and an explanation of how semaglutide economics hold up once patents expire in the 2030s.^[1][2]

The backdrop is a stock trading near the bottom of its 52-week range, at $44.56 on September 9 against a high of $64.16 and a low of $35.12, even though the underlying business has been performing.^[2] Obesity sales grew 16% last quarter, and the oral Wegovy pill has passed five million total prescriptions, with the latest million added in just four weeks, giving it roughly 90% of the U.S. oral obesity market.^[2] Second-quarter revenue of DKK 78,488 million beat estimates by nearly 10%, and management raised full-year guidance for the second time this year, though only to a range of 0% to -6% adjusted sales growth at constant currencies.^[2]

The pipeline news has been mixed. On September 7, Novo halted two more cardiovascular trials of ziltivekimab, HERMES and ATHENA, after a monitoring committee found them unlikely to succeed, following the July failure of the ZEUS outcomes trial, which lowered inflammation markers but did not reduce major heart events.^[1][2] Novo's chief scientific officer told analysts the cardiovascular program had always carried roughly a 50% or lower chance of success.^[2] The same day, Novo reported a win: a pediatric obesity trial showed 40.4% of children ages 6 to under 12 were no longer classified as obese after 68 weeks, though the stock still fell because investors weighed the cardiovascular failure more heavily.^[2]

Outside the U.S., Novo's international pill rollout is the strongest card management has going into the meeting. Three weeks into the U.K. launch, the company estimated about 300,000 patients had started the Wegovy pill, lifting its U.K. obesity market share from roughly 30% to 45%, even though only 1.6 million of an estimated 20 million obese U.K. adults are currently treated.^[2] Germany's launch follows in September, with China after that.^[2]

Why it matters for patients

The questions analysts are asking are really questions about access. Manufacturing capacity plans matter because past supply shortfalls limited who could get Wegovy and when.^[1] Pricing questions tie directly to what U.S. patients pay: separate reporting flags a Novo agreement on most-favored-nation pricing that could reach millions of patients even as some states push back, and a broader White House drug-pricing plan that could push companies to raise prices outside the U.S. to offset lower U.S. prices.^[1] The ziltivekimab failures do not affect currently available GLP-1 medications like Ozempic, Wegovy, or Rybelsus, but they narrow Novo's pipeline outside obesity and diabetes, which matters for patients hoping for new treatment options down the line.^[1][2] And the debate over semaglutide economics into the 2030s patent cliff is really a debate about how long current prices might last before lower-cost versions can enter the market.^[1][2]

What happens next

Novo holds its Capital Markets Day on September 21 in London.^[1] A decision on the experimental obesity drug CagriSema in the U.S. is expected by the end of 2026.^[2] The surviving ziltivekimab heart-attack trial, ARTEMIS, is due to read out in the first half of 2027.^[2] Management has said it will not give full 2027 financial guidance until its results are reported in February.^[2]